drugset
drugset / Trial / NCT04860635

Safety of F14 Following Total Knee Replacement

NCT04860635 ↗

Phase 2/3 Suspended 100 enrolled Arthritis Innovation Corporation
NaSingle-groupOpen-labelTreatment

Summary

Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia

Timeline

Start
2027-01
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified — Other

Indications

No indication recorded.